The fourth in this week’s series, building on earlier pieces, brings the focus squarely onto the PBS, arguing that spending on medicines has not truly slowed, but has shifted decisively from government to consumers, reshaping how the PBS functions, what it can fund, and the policy choices now confronting decision-makers.
The PBS paradox - a rising medicine spend, but a shrinking investment capacity
January 20, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The Dispatched Podcast 'Week in Review' - 20 February
February 20, 2026 - - Podcast -
PhRMA launches new campaign against the backdrop of a more assertive U.S.
February 19, 2026 - - Latest News -
Why does anyone accept a review outcome that simply affirms a settled order
February 19, 2026 - - Latest News -
Wesfarmers Health emerges as growth engine after delivering strong first half
February 19, 2026 - - Australian Biotech -
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech

